omniture
Goby Global

Latest News

D3 Bio Completes Series A+ Round to Advance Innovative Oncology Pipeline

SHANGHAI, April 8, 2024 /PRNewswire/ -- D3 Bio, an emerging global biotechnology company that focus...

2024-04-08 15:00 1374

D3 Bio Appoints Dr. Antoine Yver as Independent Board Member

SHANGHAI, March 14, 2024 /PRNewswire/ -- D3 Bio, an emerging global biotechnology company that focu...

2024-03-14 22:30 1867

Biotheus Enters Into Strategic Partnership with BioNTech to Develop and Commercialize Bispecific Antibody Candidate Targeting PD-L1 and VEGF in Multiple Solid Tumor Indications

Bispecific Antibody Candidate PM8002 demonstrated encouraging data at this year's ASCO Annual Meeti...

2023-11-06 20:00 2221

Biotheus Announces Strategic Research Collaboration and Worldwide License Agreement with BioNTech

ZHUHAI, China, July 19, 2023 /PRNewswire/ -- Biotheus Inc. ("Biotheus"), a clinical-stage biotech c...

2023-07-20 09:01 1945

Chance Pharmaceuticals and Acorda Therapeutics Announce Agreement to Provide INBRIJA® in Greater China

HANGZHOU, China, May 8, 2023 /PRNewswire/ -- Chance Pharmaceuticals and Acorda Therapeutics, Inc. t...

2023-05-08 19:30 1660

Createrna Announces Positive Top-Line Results from Phase 1 Clinical Trials of QR052107B Tablet in Healthy Volunteers

* QR052107B Tablet was safe and well tolerated in healthy volunteers across all tested doses, wi...

2022-12-08 14:29 1923

Impact Therapeutics Announces Completion of Series D1 Financing

SHANGHAI, March 14, 2022 /PRNewswire/ -- IMPACT Therapeutics, a biopharmaceutical company dedicated...

2022-03-14 12:43 1854